Press Releases All News 2019 2018 2017 2016 2015 2014 Relmada Therapeutics to Present at LD Micro Invitational Conference in Los Angeles June 3, 2019 Relmada Therapeutics Presents Development Program of REL1017 for Treatment of Depression at the 2019 American Society of Clinical Psychopharmacology Meeting May 31, 2019 Relmada Therapeutics Announces Publication of REL1017 Phase 1 Studies Results April 16, 2019 Gina DiGuglielmo Joins Relmada as Vice President and Head of Clinical Operations April 3, 2019 Relmada Therapeutics to Present at Biotech Showcase 2019 January 2, 2019 Relmada Therapeutics Presents Clinical Data on Increased BDNF Plasma Levels in Subjects Treated with REL-1017 December 12, 2018 Relmada Therapeutics to Present Clinical Data on the Effect of REL-1017 on BDNF Plasma Levels October 2, 2018 Relmada Therapeutics Provides Enrollment Update in Phase 2 Study of REL-1017 in Patients with Major Depressive Disorder September 18, 2018 Relmada Therapeutics Allowed Patent Application in China Covering NMDA Receptor Antagonist d-Methadone for Treatment of Psychiatric Symptoms August 9, 2018 Relmada Therapeutics Inc. Announces First Patient Dosed in Phase 2 Study of REL-1017 in Patients with Major Depressive Disorder June 27, 2018 1 2 3 4 5 6 7 8 9 10 ...12 Next »
Relmada Therapeutics Presents Development Program of REL1017 for Treatment of Depression at the 2019 American Society of Clinical Psychopharmacology Meeting May 31, 2019
Relmada Therapeutics Presents Clinical Data on Increased BDNF Plasma Levels in Subjects Treated with REL-1017 December 12, 2018
Relmada Therapeutics to Present Clinical Data on the Effect of REL-1017 on BDNF Plasma Levels October 2, 2018
Relmada Therapeutics Provides Enrollment Update in Phase 2 Study of REL-1017 in Patients with Major Depressive Disorder September 18, 2018
Relmada Therapeutics Allowed Patent Application in China Covering NMDA Receptor Antagonist d-Methadone for Treatment of Psychiatric Symptoms August 9, 2018
Relmada Therapeutics Inc. Announces First Patient Dosed in Phase 2 Study of REL-1017 in Patients with Major Depressive Disorder June 27, 2018
